ClinicalTrials.gov posted results on 20 August 2026 from a terminated Phase II trial of nivolumab plus ipilimumab in patients with renal medullary carcinoma. The study enrolled 10 participants; the registry reported 0 participants with an objective response and 0 participants with disease control.
Background
The trial evaluated nivolumab and ipilimumab in kidney medullary carcinoma and in patients with loss of INI 1 protein expression, as well as stage III or stage IV renal cell cancer defined by AJCC version 8. The registry describes both medicines as monoclonal-antibody immunotherapies that may help the body's immune system attack cancer and may interfere with tumor-cell growth and spread.
Trial design
This was a Phase II trial listed as terminated, with an enrollment of 10 participants. The registered interventions were intravenous nivolumab and intravenous ipilimumab. The data supplied do not include a primary-outcome measurement or comparator arm. Reported outcomes included objective response rate, overall survival, progression-free survival, and disease control rate.
Key results
For the nivolumab combination with ipilimumab, the objective response rate measurement was 0 participants. The disease control rate measurement was also 0 participants.
The registry reported two median measurements of 1.38 months and 8.23 months for the combined outcome listing of overall survival, progression-free survival, and disease control rate. The supplied data do not identify which median corresponds to overall survival or progression-free survival, and no confidence-interval values were provided despite a 95% confidence-interval label.
No key statistical analyses, p-values, or adverse-event summary were included in the supplied record data.
What this means
The posted record describes results from a small, terminated study of nivolumab plus ipilimumab in renal medullary carcinoma. In the available measurements, no participants were recorded as having an objective response or disease control. The data do not provide a comparator-based efficacy assessment, statistical testing, or a safety conclusion.
Source
Source: ClinicalTrials.gov, trial-results record for NCT03274258, posted 20 August 2026. The registry record is available at clinicaltrials.gov/study/NCT03274258.